Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Advances deployment of mRNA technology across vaccines and therapeutics development
The COVID Working Group has recommended extension of the gap between the first and second doses of Covishield
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
India business grew 11.8% YoY vs mid-single digit industry growth.
Subscribe To Our Newsletter & Stay Updated
